Hesham Nawar received his PhD in Microbiology and Immunology from the State University of New York at Buffalo in 2006. He completed postdoctoral training at Harvard Medical School/Massachusetts General Hospital (2007–2008). He joined the FDA as an ORISE fellow focusing on the development of the Meningococcal B vaccine. In 2013, Hesham transitioned to the pharmaceutical industry as he worked at Sanofi and Merck. He is currently holding the position of Analytical Development Director leading the Bioassay team. The team is supporting early- and late-stage gene therapy products focusing on Cell-Based potency assays.
Hesham Nawar received his PhD in Microbiology and Immunology from the State University of New York at Buffalo in 2006. He completed postdoctoral training at Harvard Medical School/Massachusetts General Hospital (2007–2008). He joined the FDA as an ORISE fellow focusing on the development of the Meningococcal B vaccine. In 2013, Hesham transitioned to the pharmaceutical industry as he worked at Sanofi and Merck. He is currently holding the position of Analytical Development Director leading the Bioassay team. The team is supporting early- and late-stage gene therapy products focusing on Cell-Based potency assays.